hVIVO Announces Annual Report and Directorate Changes

Open Orphan Plc ( (GB:HVO) ) has shared an announcement.

hVIVO plc has announced the release of its Annual Report and Accounts for 2024, along with the Notice of its upcoming Annual General Meeting (AGM). The company also disclosed a directorate change, with Non-Executive Director Martin Gouldstone stepping down to focus on other business interests, and Cathal Friel, the co-founder and Chair, not seeking re-election. Dr. Elaine Sullivan will serve as Interim Chair until a permanent successor is appointed. These changes are expected to bring new expertise and leadership to hVIVO as it continues to execute its strategic objectives.

Spark’s Take on GB:HVO Stock

According to Spark, TipRanks’ AI Analyst, GB:HVO is a Outperform.

hVIVO plc is in a strong financial position with robust revenue growth and low leverage. The stock shows promising technical momentum and appears undervalued given its P/E ratio. Recent strategic acquisitions and contracts enhance growth prospects, although governance concerns need monitoring.

To see Spark’s full report on GB:HVO stock, click here.

More about Open Orphan Plc

hVIVO plc is a full-service Contract Research Organisation (CRO) and the global leader in human challenge trials. The company provides comprehensive clinical development services to a diverse client base, including major biopharma companies. It specializes in human challenge trials for infectious and respiratory diseases, operates a large quarantine facility in London, and offers virology and immunology laboratory services. Through its subsidiaries, hVIVO also provides early-phase clinical trial services and drug development consulting.

Average Trading Volume: 1,848,378

Technical Sentiment Signal: Sell

Current Market Cap: £120.2M

For detailed information about HVO stock, go to TipRanks’ Stock Analysis page.